A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs

Vleeschauwer, Annebel R. De; Zhou, Xiaocui; Lefebvre, David; Garnier, Annabelle; Watier, Fleur; Pignon, Charly; Lacour, Sandrine; Zientara, Stéphan; Bakkali‐Kassimi, Labib; Clercq, Kris De; Klonjkowski, Bernard

doi:10.1016/j.vaccine.2018.02.074

Cited by 12 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, RDAd vaccine expressing only the FMDV VP1 capsid protein can only induce low levels of neutralizing antibodies [61], whereas RDAd vaccines expressing the complete P1-encoded capsid polypeptide of FMDV and the 3C pro protease can fully protect swine and cattle [58,62,63]. Protection was also achieved in animal models with this FMDV antigen formulation expressed in an RDCaAd2 vector instead of the "traditional" RDHuAd5 vector [56], highlighting the efficacy of this antigen construct. The choice of antigen for vaccination should, therefore, be based on the knowledge of host-pathogen interactions and the characterization of the protective immunity that arises during infection.…”

Section: Antigen-encoding Rdad As Vaccinesmentioning

confidence: 98%

“…One of the main barriers for the development of nonhuman RDAd vectors is the necessity to construct cell lines capable of complementing the viral genome so that these vaccines can be propagated. The production of RD vectors has nonetheless been achieved for several nonprimate species [48,53], and RDCaAd2 vectors expressing immunogenic viral subunits have shown potential for vaccination against rabies [54], bluetongue virus (BTV) [55], or FMDV [56]. Because Ad infect a wide range of mammalian cells from different species, these nonhuman RDAd vectors could also be used to circumvent pre-existing immunity.…”

Section: Human Vs Nonhuman Adenovirus For Veterinary Usementioning

confidence: 99%

See 1 more Smart Citation

Adenovirus as Tools in Animal Health

Rojas¹,

Sevilla²,

Martı́n³

2019

Adenoviruses

View full text Add to dashboard Cite

Adenoviruses have long been identified as good candidates for use as viral vectors in gene therapy and as vaccines. These viruses can infect multiple cell types, while in division or in quiescence, and are relatively easy to manipulate so that parts of their genome can be replaced with exogenous genes. Progressive safety improvements in replication-deficient adenoviral vectors have been achieved with the second and third generation, and ending with the gutless adenoviral vectors. Adenoviral vectors are immunogenic and can act as adjuvants. Nonetheless, the potency of human recombinant adenoviral vaccines was below expectations in clinical trials mainly because of the pre-existing adenoviral immunity found in the general population. This drawback can however become advantageous in animal health, as no previous immunity to human adenoviral vectors exists in animals. Other viral vectors viruses are used as vaccine, but adenoviruses remain the most employed and promising recombinant vector in veterinary medicine. In this chapter, we review the generation of adenoviral vectors, the immune response they trigger, and their advantages and disadvantages for veterinary use in terms of safety and efficacy. This chapter also describes how recombinant adenoviral vectors can be integrated as tools for vaccination and immunomodulation in veterinary medicine.

show abstract

Section: Antigen-encoding Rdad As Vaccinesmentioning

confidence: 98%

Section: Human Vs Nonhuman Adenovirus For Veterinary Usementioning

confidence: 99%

Adenovirus as Tools in Animal Health

Rojas¹,

Sevilla²,

Martı́n³

2019

Adenoviruses

View full text Add to dashboard Cite

show abstract

“…All the HPV L1 reference sequences of 6,16,18,31,33,34,35,45,52, and 58 were obtained from the PaVE website (http://pave.niaid.nih.gov) (GenBank accession number GI:60955, GI:333031, GI:60975, GI:333048, GI:333049, GI:9627334, GI:396997, GI:397022, GI:397038, and GI:222386, respectively). It was previously shown that a human codon optimized L1 gene resulted in higher accumulation of L1 when expressed in plants compared to expression of plant codon optimized and native L1 gene sequences [23].…”

Section: Hpv Recombinant Plasmidsmentioning

confidence: 99%

“…The plant-produced VLP vaccine candidates and empty vector negative control were emulsified in mineral oil MONTANIDE™ ISA 50 V2 adjuvant at a 60:40 (vaccine:adjuvant) ratio. MONTANIDE ISA 50 V2 is a ready-to-use oily vaccine adjuvant that has previously been used in mice [33,34]. Purified plant-produced HPV L1 proteins were used as coating antigens in ELISAs.…”

Section: Immunization Of Micementioning

confidence: 99%

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

et al. 2020

View full text Add to dashboard Cite

Cervical cancer is ranked fourth among the top cancers in women and is the second most common cancer in low- and middle-income regions, with ~570,000 new cases reported in 2018, which attributed to 84% of worldwide cervical cancer cases. Three commercially available prophylactic Human papillomavirus (HPV) vaccines are effective at preventing HPV infections. However, these vaccines are expensive due to their complex production systems, therefore limiting their use in developing countries. Recently, the use of plants to produce vaccines has emerged as a cost-effective alternative to conventionally used expression systems. Here, L1 proteins of eight high-risk (HPV 16, 18, 31, 33, 35, 45, 52, and 58) and two low risk (HPV 6 and 34) HPV types were successfully expressed in Nicotiana benthamiana, and transmission electron microscopy (TEM) analysis showed the presence of VLPs and/or capsomeres. Immunogenicity studies were conducted in mice utilizing HPV 35, 52, and 58 and showed that type-specific L1-specific antibodies were produced which were able to successfully neutralize homologous HPV pseudovirions in pseudovirion-based neutralization assays (PBNAs). This work demonstrated the potential for using plant-based transient expression systems to produce affordable and immunogenic HPV vaccines, particularly for developing countries.

show abstract

“…Foot-and-mouth disease (FMD) is one of the most important infectious diseases of cloven-hoofed livestock and wildlife [1] , which is an acute, hot, and highly contagious infectious disease caused by the foot-and-mouth disease virus (FMDV). In 2007, the British FMD epidemic caused a major blow to the export of cloven-hoofed animals and their products (http :// www.…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review and Meta-analysis of the Protective Effect of FMDV VP1 on Animals

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

The FMDV VP1 protein has different structures which could decrease or increase the immune response. We undertook a meta-analysis to evaluate the protective effect of VP1 on the FMDV. A systematic search of the PubMed, Embase, CNKI and Wan fang DATA was conducted up to April 2020. Experimental studies involving the VP1 protection effect on FMDV were included. Extracted data were analyzed using Rev-Man 5.3 software. Chi-square tests were used to analyze the heterogeneity among the documents. The fixed-effect model was used for meta-analysis to find the combined effect value and 95% confidence interval. Sensitivity analysis was performed on the differences in the combined values of model effects, and the inverted funnel chart method was used to assess the publication bias of the included literature. A total of 12 articles were included for meta-analysis. The results of showed that VP1 had a protective effect on FMDV [MH = -0.66, 95% CI = (−0.75, -0.56), P < 0.00001]. Sensitivity analysis showed that the results were robust. The funnel graph method showed that the published literature had a small publication bias and met the requirements of this study. It is necessary to study the epitopes of VP1 to produce new vaccines. VP1 could protect animals from FMDV attacks. It is necessary to study the VP1 protein and its epitopes and use it as a new vaccine and diagnostic product.

show abstract

A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs

Cited by 12 publications

References 38 publications

Adenovirus as Tools in Animal Health

Adenovirus as Tools in Animal Health

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

A Systematic Review and Meta-analysis of the Protective Effect of FMDV VP1 on Animals

Contact Info

Product

Resources

About